drug
oritavancin diphosphate
Marketedupdated 3mo agoby A. Menarini Industrie Farmaceutiche Riunite Srl
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying oritavancin diphosphate
- phase2Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections
- phase1A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants
- phase1Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects
- phase1Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 29, 2029
~3.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Jul 16, 2035formulationUS 9649352
- Apr 26, 2030method-of-use (U-1569)US 96820613.7y
- Aug 29, 2029method-of-use (U-4398)US 125148993.0y
- Aug 29, 2029method-of-use (U-1570)US 84205923.0y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that